Key Patent Covers Manufacture of Thera­peutic Products Containing a High Percentage of T Stem Cell Memory Cells

San Diego, CA (Press Release) – Poseida Thera­peutics Inc., a clin­i­cal-stage bio­pharma­ceu­tical com­pany leveraging pro­pri­e­tary non-viral gene engi­neer­ing tech­nolo­gies to create life-saving thera­peutics, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allow­ance for a patent pro­tecting the method of producing genetically modified T cells with a high per­cent­age of stem cell memory T cells (Tscm).

Tscm cells are long-lived, self-renewing and multipotent. These cells have the capacity to reconstitute the entire spectrum of effector and memory T cells subsets and usually sur­vive for decades and poten­tially for entire lifespans. The wholly-owned patent covers the method of producing genetically modified T cell prod­ucts that are com­prised of 25% or more Tscm cells.

“These addi­tions to our patent port­folio further val­i­date the novel ad­vancements we have made in Tscm-based prod­uct can­di­dates,” said Eric Ostertag, M.D., Ph.D., chief exec­u­tive officer of Poseida. “Our inno­va­tive CAR-T prod­uct can­di­dates, uti­liz­ing a pro­pri­e­tary non-viral de­livery method, are com­prised of a high per­cent­age of stem cell memory T cells, which we believe are im­por­tant for safety and efficacy of CAR-T ap­proaches to treat both liquid and solid tumors.”

The Com­pany’s lead prod­uct can­di­date, P-BCMA-101, is an au­tol­o­gous CAR-T thera­peutic can­di­date to treat patients with re­lapsed / re­frac­tory multiple myeloma. This and other prod­uct can­di­dates cur­rently in devel­op­ment are com­prised of a high per­cent­age of Tscm cells.

The Com­pany has also re­ceived a Notice of Allowance on a patent that is part of a broader port­folio pro­tecting its piggyBac® DNA Modification System, a pro­pri­e­tary non-viral DNA de­livery method. The Com­pany also re­ceived approval for registered trademarks of both “piggyBac” and “Footprint-Free®”, the latter referring to a plat­form tech­nology designed to allow for gene edit­ing of as little as a single nucle­o­tide in 100% of target cells.

About Poseida Thera­peutics, Inc.

Poseida Thera­peutics is a clin­i­cal-stage bio­technology com­pany leveraging pro­pri­e­tary next-generation non-viral, gene engi­neer­ing tech­nolo­gies to create life-saving thera­peutics for patients with high unmet medical need. The com­pany is devel­op­ing a wholly-owned pipe­line of au­tol­o­gous and allo­geneic CAR-T prod­uct can­di­dates, initially focused on the treat­ment of hema­to­logical malig­nan­cies and solid tumors. Poseida’s prod­uct can­di­dates are designed to address the limitations of other CAR-T ther­a­pies, in­­clud­ing duration of re­sponse­, the ability to treat solid tumors and safety con­cerns.

Source: Poseida Thera­peutics.